EUCTR2014-004610-29-SE进行中(未招募)1 期
Ciclosporin to Protect Renal function In Cardiac Surgery. CiPRICS. A Phase II Double Blind Randomized Placebo Controlled Study. - CiPRICS
Skanes University Hospital0 个研究点开始时间: 2014年12月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.The study patient is scheduled for non-emergent (decision to operate more than one hour before start of surgery) CABG surgery.
- •2.Preoperative CyC eGFR or MDRD eGFR is 15-90.
- •eGFR will be calculated using both creatinine (MDRD) and CyC .
- •The lowest eGFR value will be used as inclusion criteria.
- •3.The patient has given his/her written consent to participate.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 85
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 85
排除标准
- •1.The patient has an uncontrolled hypertension.
- •2.Hypersensitivity to the active drug or vehicle, including egg-,
- •soya- or peanut protein;.
- •3.The patient is pregnant or is a fertile woman.
- •4.The patient has been treated with ciclosporin within 4 weeks
- •prior to the surgery.
- •5.The patient has a known ongoing malignancy.
- •6.The patient has ongoing immunosuppressive treatment.
- •7.The patient has severe hepatic dysfunction.
- •8.The patient is treated with dialysis.
- •9.The patient has pre-operatively ongoing and/or increasing clinical infection with CRP levels of >50 mg/L. Clinical signs of infection may or may not be present. Increase in CRP due to signs of cardiac origin, according to the investigator, should not be considered as exclusion criteria.
- •10.The patient has a severe ongoing viral infection, including HIV, hepatitis C, current or history of hepatitis B.
- •11. For non-allowed and restricted ongoing and concomitant medications, see Protocol section 12.2.
- •12.The patient is planned for Off-pump CABG surgery.
- •13.The patient is included in other ongoing clinical trial.
- •14.For any other reason, the patient is unsuitable to
- •participate in the study, according to the investigator.
研究者
相似试验
已完成
2 期
Ciclosporin to Protect Renal Function In Cardiac SurgeryAcute Kidney InjuryNCT02397213Region Skane155
进行中(未招募)
不适用
EPO to protect renal function after cardiac surgery. EPRICS. A phase II double blind randomized controlled study. - EPRICSEUCTR2011-001673-70-SESkånes Universitetssjukhus
进行中(未招募)
1 期
se of levosimendan / placebo as cardio and nephroprotection in patients who are going 0n cardiac surgery with right ventricular dysfunctioEUCTR2018-004063-31-ESFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)20
进行中(未招募)
1 期
MERCURI-2AKICTIS2024-515260-31-00Stichting Amsterdam UMC784
已完成
不适用
Renoprotective effect of Calcium channel blocker or Diuretics treatment with Renin-Angiotensin system(RAS) inhibitor in hypertensive patients with chronic kidney disease(CKD) (CD Study)Hypertensive patients with CKD under the treatment of the inhibitor of the renin-angiotensin system(RAS)JPRN-UMIN000004304iigata University300
